MFat vs Corticosteroid Injection for Knee Osteoarthritis

(ARISE Trial)

No longer recruiting at 20 trial locations

Overseen By Kenneth Bunch, MD

Age: 18+

Sex: Any

Trial Phase: Phase 3

Sponsor: Lipogems International spa

Must not be taking: Oral corticosteroids, Anti-coagulants

Disqualifiers: Rheumatoid arthritis, Infection, Obesity, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 4

Duration: 1 day

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to compare two treatments for knee osteoarthritis pain and function: a corticosteroid injection and an injection of microfragmented adipose tissue (Mfat), derived from the patient's own fat. Participants will receive one of these injections to determine which is more effective in easing symptoms. The study seeks individuals with knee osteoarthritis who have tried other treatments, such as physical therapy and over-the-counter pain medication, for at least three months without success. As a Phase 3 trial, this study serves as the final step before FDA approval, providing participants an opportunity to access potentially effective treatments early.

Will I have to stop taking my current medications?

Participants must stop using over-the-counter pain medications like Acetaminophen or NSAIDs for 7 days before any follow-up visit and abstain from NSAIDs for 7 days before and 2 weeks after the injection. Prescription pain or anti-inflammatory medications must be stopped for the study duration, except for Tramadol immediately after the procedure.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that injections of microfragmented adipose tissue (MFat) are generally safe for treating knee osteoarthritis. MFat uses a person's own fat tissue, reducing the risk of immune problems and adverse reactions. Specifically, MFat injections have improved knee function and reduced pain for up to four years, with no major safety concerns reported.

Corticosteroid injections, another well-known treatment for knee pain, have been used for many years. They are usually well-tolerated, though some people might experience temporary side effects like joint pain or swelling after the injection.

Both treatments have demonstrated promising safety results, making them good options for those considering participation in a trial for knee osteoarthritis. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about Microfragmented Adipose Tissue (MFat) for knee osteoarthritis because it uses a unique approach by leveraging the body’s own fat tissue to potentially heal and reduce inflammation in the knee. Unlike traditional treatments like corticosteroid injections, which primarily focus on reducing inflammation temporarily, MFat involves extracting and processing a patient’s own fat tissue, which is then injected back into the knee. This approach not only offers a natural alternative but is also believed to provide longer-lasting relief by directly promoting tissue repair and regeneration. Additionally, using the body’s own cells minimizes the risk of rejection and adverse reactions, making it a promising new avenue for osteoarthritis treatment.

What evidence suggests that this trial's treatments could be effective for knee osteoarthritis?

This trial will compare the effectiveness of microfragmented adipose tissue (MFat) and corticosteroid injections for knee osteoarthritis. Research has shown that MFat can help with knee osteoarthritis, with 68% of patients reporting improvement four years after treatment. This method uses the patient's own fat to reduce pain and improve knee function. Studies using the Knee injury and Osteoarthritis Outcome Score (KOOS) have consistently demonstrated benefits over time. MFat has also aided patients with related conditions like atherosclerosis. Overall, MFat appears to offer significant benefits for individuals with knee osteoarthritis.

Participants in this trial may also receive corticosteroid injections, another common treatment for knee osteoarthritis. These injections reduce inflammation and pain, but the relief might be temporary and may not address the underlying issue. Both treatments can alleviate pain, but their long-term effects may differ. ^{1 5 6 7 8}

Are You a Good Fit for This Trial?

Adults over 18 with knee osteoarthritis (Grade 2-3) who've had pain despite trying physical therapy and NSAIDs for at least 3 months can join. They must be able to attend follow-ups, read English, and not be pregnant or breastfeeding unless postmenopausal or sterilized. Excluded are those with severe obesity, certain knee deformities, autoimmune diseases needing immunosuppressants, allergies to specific drugs used in the trial, uncontrolled diabetes or blood pressure issues, recent injections or surgeries on the knee.

Inclusion Criteria

You are willing to provide written consent and sign the HIPAA Authorization before taking part in this study.

My knee pain and X-rays show I have osteoarthritis.

I have had knee pain for over 3 months that hasn't improved with basic treatments.

Exclusion Criteria

Respiratory Rate <9 or >20

I have had knee surgery within the last 6 months.

I have knee pain due to a specific bone condition, ligament damage, or a severe meniscus tear.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single intra-articular injection of either MFat or corticosteroid at the baseline visit

1 day

1 visit (in-person)

Follow-up

Participants are monitored for changes in pain and function using the WOMAC index at 6, 9, and 12-month follow-up visits

12 months

3 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

• Corticosteroid
• Microfragmented Adipose Tissue

Trial Overview The study is testing a single injection treatment for knee osteoarthritis pain and function: one group receives microfragmented adipose tissue (MFat), while another gets a corticosteroid injection. The effectiveness of these treatments will be compared.

How Is the Trial Designed?

Group I: Microfragmented Adipose Tissue (Mfat) Experimental Treatment 1 Intervention

Injection of Microfragmented Adipose Tissue derived using Lipogems® Kit The cases assigned to this group will be injected intra-articularly with Lipogems®. The patients will undergo lipoaspiration of their own adipose tissue for Mfat then this Mfat will be injected intra-articularly in the knee. It will be administered once at the baseline visit of the study.

Group II: Corticosteroid Injection Active Control 1 Intervention

The cases assigned to this group will be injected intra-articularly in the knee with a corticosteroid. It will be administered once at the baseline visit of the study.

Corticosteroid is already approved in United States, European Union for the following indications:

Approved in United States as Singulair for:

• Asthma
• Exercise-induced bronchoconstriction
• Seasonal allergic rhinitis
• Perennial allergic rhinitis

Approved in European Union as Singulair for:

• Asthma
• Exercise-induced bronchoconstriction
• Seasonal allergic rhinitis
• Perennial allergic rhinitis

Who Is Running the Clinical Trial?

Lipogems International spa

Lead Sponsor

Trials

4

Recruited

540+

Alira Health

Collaborator

Trials

6

Recruited

4,200+

Alira Health

Collaborator

Trials

6

Recruited

4,200+

Published Research Related to This Trial

In a study involving 84 patients with symptomatic knee osteoarthritis, a 10-mg dose of triamcinolone acetonide was found to be non-inferior to a 40-mg dose in reducing pain after 12 weeks, indicating that lower doses can be just as effective.

Both the 10-mg and 40-mg doses significantly improved pain and quality of life for patients, suggesting that lower doses may provide a safer option without compromising efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The efficacy of intra-articular triamcinolone acetonide 10 mg vs. 40 mg in patients with knee osteoarthritis: a non-inferiority, randomized, controlled, double-blind, multicenter study. Utamawatin, K., Phruetthiphat, OA., Apinyankul, R., et al.[2023]

In a phase IIa study involving 24 patients with bilateral knee osteoarthritis, the intra-articular injection of triamcinolone acetonide extended release (TA-ER) was well tolerated and showed a lower peak plasma concentration of the drug compared to traditional triamcinolone acetonide crystalline suspension (TAcs).

The study demonstrated that TA-ER resulted in lower systemic exposure to triamcinolone acetonide after bilateral injections, suggesting it may be a safer option for patients needing simultaneous treatment in both knees.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A randomized, phase IIa study to assess the systemic exposure of triamcinolone acetonide following injection of extended-release triamcinolone acetonide or traditional triamcinolone acetonide into both knees of patients with bilateral knee osteoarthritis. Kivitz, A., Kwong, L., Shlotzhauer, T., et al.[2022]

A 40 mg intra-articular injection of methylprednisolone acetate (MPA) can provide clinical benefits for knee osteoarthritis symptoms, but careful consideration of factors like pain severity and individual patient circumstances is crucial for effectiveness.

There are significant safety concerns and contraindications associated with MPA injections, especially regarding patients on anticoagulants, highlighting the need for individualized treatment plans and thorough risk-benefit evaluations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Therapeutic Review of Methylprednisolone Acetate Intra-Articular Injection in the Management of Osteoarthritis of the Knee - Part 2: Clinical and Procedural Considerations. McCrum, C.[2018]

In a study of 110 knees, a single ultrasound-guided injection of microfragmented adipose tissue (MFAT) significantly reduced pain (VAS score improved from 70 to 30) and enhanced functionality (OKS score improved from 25 to 33.5) in patients with knee osteoarthritis over a 12-month period.

No adverse events were reported during or after the procedure, indicating that MFAT injections are a safe treatment option for knee osteoarthritis, with promising improvements in patient quality of life (EQ-5D score improved from 0.62 to 0.69).

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Patient-Centered Outcomes of Microfragmented Adipose Tissue Treatments of Knee Osteoarthritis: An Observational, Intention-to-Treat Study at Twelve Months. Heidari, N., Noorani, A., Slevin, M., et al.[2022]

In a study involving 60 patients undergoing bilateral total knee arthroplasty, the use of a multimodal cocktail injection with corticosteroids did not show significant differences in pain relief, motion range, or swelling compared to injections without corticosteroids.

The findings suggest that multimodal periarticular injections without corticosteroids can effectively manage postoperative pain and swelling, indicating that corticosteroids like betamethasone may not be necessary for optimal outcomes in this context.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Local Efficacy of Corticosteroids as an Adjuvant for Periarticular Cocktail Injection in Simultaneous Bilateral Total Knee Arthroplasty: A Prospective Randomized Double-Blind Controlled Trial. Peng, H., Wang, W., Lin, J., et al.[2021]

Local corticosteroid injections are generally safe and can effectively manage symptoms in conditions like rheumatoid arthritis and knee osteoarthritis, providing relief for up to three months in some cases.

While these injections can help with acute flare-ups and certain symptoms, they do not significantly prevent joint damage or erosive changes, and their use should complement other treatments like physical therapy and disease-modifying drugs.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Intra-articular corticosteroids. An updated assessment. Gray, RG., Gottlieb, NL.[2006]

A single injection of autologous microfragmented adipose tissue (MFAT) significantly improved clinical outcomes, including pain and quality of life, in 75 elderly patients with knee osteoarthritis over a two-year follow-up period.

The best results were observed in patients with early-stage osteoarthritis (KL grade 2), but overall, 88.3% of treatments showed significant functional improvement across all grades of knee OA, suggesting MFAT is a safe and effective alternative treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Two-year clinical outcomes of autologous microfragmented adipose tissue in elderly patients with knee osteoarthritis: a multi-centric, international study. Gobbi, A., Dallo, I., Rogers, C., et al.[2021]

A single intra-articular injection of autologous microfragmented adipose tissue (MFAT) showed a short-term therapeutic response rate of 64% at 3 months and 45% at 12 months in 64 patients with symptomatic knee osteoarthritis, indicating early clinical improvement but a decline in effectiveness over time.

The study found that the presence of bone marrow lesions negatively impacted the therapeutic response rate, suggesting that assessing these lesions could help identify patients who may benefit more from MFAT treatment, potentially increasing the response rate to 70% at 12 months.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Autologous Micro-Fragmented Adipose Tissue (MFAT) to Treat Symptomatic Knee Osteoarthritis: Early Outcomes of a Consecutive Case Series. Van Genechten, W., Vuylsteke, K., Martinez, PR., et al.[2021]

Injectable corticosteroids can cause side effects like lipoatrophy, especially when misused by non-dermatologists, highlighting the need for careful administration.

Serial saline injections have been found to be a safe, quick, and cost-effective treatment for steroid-induced lipoatrophy in children, providing a practical alternative to manage this side effect.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Reversal of steroid-induced lipoatrophy with serial injections of isotonic saline in a child. Daruwalla, SB., Dhurat, RS., Sharma, A., et al.[2021]

In a study involving 118 patients with knee osteoarthritis, both microfragmented adipose tissue (MF-AT) and platelet-rich plasma (PRP) injections led to significant improvements in knee function and pain relief over 24 months, with no notable differences in outcomes between the two treatments.

While MF-AT and PRP showed similar efficacy, a higher percentage of patients with moderate to severe OA in the MF-AT group achieved clinically meaningful improvements in knee function at 6 months, suggesting a potential advantage for certain patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Microfragmented Adipose Tissue Versus Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Prospective Randomized Controlled Trial at 2-Year Follow-up. Zaffagnini, S., Andriolo, L., Boffa, A., et al.[2023]

In a study of 71 patients with early hip osteoarthritis, injections of autologous micro-fragmented adipose tissue (MFAT) led to significant clinical improvements, with 28 patients not requiring further treatment after an average follow-up of 29 to 41 months.

The Oxford Hip Score improved by an average of 6.9 points post-treatment, indicating that MFAT injections can be an effective option for managing symptoms in early to moderate hip osteoarthritis.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Is intra-articular injection of autologous micro-fragmented adipose tissue effective in hip osteoarthritis? A three year follow-up. Natali, S., Screpis, D., Romeo, M., et al.[2023]

In a study involving 100 patients with knee osteoarthritis, both triamcinolone hexacetonide (TH) and methylprednisolone acetate (MA) injections significantly reduced pain at 4 weeks, with sustained improvements observed up to 24 weeks.

There was no significant difference in efficacy between TH and MA, as both treatments showed similar outcomes in pain relief and functional improvement, indicating that either corticosteroid can be effectively used for managing knee OA.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy of Triamcinolone Hexacetonide versus Methylprednisolone Acetate Intraarticular Injections in Knee Osteoarthritis: A Randomized, Double-blinded, 24-week Study. Lomonte, AB., de Morais, MG., de Carvalho, LO., et al.[2022]

Citations

1. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/38212589/

Autologous microfragmented adipose tissue treatment of ... Autologous microfragmented adipose tissue treatment of knee osteoarthritis demonstrates effectiveness in 68% of patients at 4-year follow-up.

2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC12471203/

Autologous Micro-Fragmented Adipose Tissue (MFAT) ... Outcomes were assessed using the Knee injury and Osteoarthritis Outcome Score (KOOS) subscales at baseline, 3, 6, and 12 months. A linear mixed ...

3. journals.plos.org journals.plos.org/plosone/article?id=10.1371/journal.pone.0289610

Autologous micro-fragmented adipose tissue in the treatment ... The use of micro-fragmented adipose tissue may benefit for improving symptoms of knee osteoarthritis accompanied by atherosclerosis although may lead to some ...

4. sciencedirect.com sciencedirect.com/science/article/pii/S2352320425000495

Comparison of short-term clinical outcomes of intra- ... This study aimed to compare the clinical outcomes of SVF and MFAT for knee OA, focusing on their therapeutic effects over time.

5. arthroscopytechniques.org arthroscopytechniques.org/article/S2212-6287(25)00117-3/fulltext

Autologous Microfragmented Adipose Tissue Injection ... ... (fat) tissue ... Autologous microfragmented adipose tissue treatment of knee osteoarthritis demonstrates effectiveness in 68% of patients at 4-year follow-up.

6. link.springer.com link.springer.com/article/10.1007/s00402-023-05143-y

Autologous microfragmented adipose tissue treatment of ... MFAT intra-articular injection is a safe procedure with positive improvements up to 4-year follow-up in patients with early knee OA.

7. sciencedirect.com sciencedirect.com/science/article/pii/S0976566224004739

Safety and efficacy of autologous adipose-derived stem ... The current systematic review demonstrated that using autologous adipose-derived stem cells improved clinical outcomes and is effective and safe in elderly ...

8. josr-online.biomedcentral.com josr-online.biomedcentral.com/articles/10.1186/s13018-025-06006-5

Efficacy and safety of micro-fragmented adipose tissue ... The autologous nature of MFAT not only avoids immune rejection and ethical concerns but also highlights its unique potential in KOA treatment, ...